Navigation Links
UPDATE: Nile Therapeutics Announces Positive Phase 1a Results of CD-NP, a Selective NPR-B Agonist in Clinical Development for the Treatment of Heart Failure
Date:10/11/2007

sed sodium excretion versus baseline (28%, 138%, 55% and 158% average change, respectively) and increased plasma cGMP versus baseline (4%, 202%, 378% and 691% average change, respectively).

With respect to safety assessments, CD-NP (placebo, 10, 17.5 and 25 ng/kg/min) had no effect on mean arterial pressure versus baseline (-5%, 6%, -6%, -8% average change, respectively), had no effect on serum potassium levels versus baseline (0%, -2%, 3%, 3% average change, respectively), and had no effect on renal function as measured by GFR versus baseline (1%, 8%, 3%, 4% average change, respectively).

The four-hour infusion of CD-NP was well tolerated in all subjects at all dose levels tested. At the highest dose (25 ng/kg/min) of CD-NP, after completing the four-hour infusion, in response to an orthostatic challenge, some subjects exhibited transient symptoms consistent with volume depletion and/or vasodilatation including dizziness, asymptomatic tachycardia and orthostatic hypotension. These events are indicative of a practical limit of pharmacologic activity in normal healthy subjects, and Nile intends to investigate higher doses in upcoming Phase 1b studies of CD-NP infusions in heart failure patients.

"In this trial in healthy subjects, we demonstrated that CD-NP can be safely administered and elicits pharmacological and clinical effects which are consistent with the proposed mechanism of action. We are planning additional phase 1 trials in heart failure patients with the goals of determining the therapeutic dose range for diuresis, natriuresis, and cardiac filling pressure reducing effects, while maintaining systemic blood pressure and preserving renal function," commented Peter Strumph, Chief Executive Officer of Nile.

About CD-NP

CD-NP is a rationally-designed synthetic peptide designed to incorporate the optimal components of naturally occurring natriuretic peptides, creating a novel compound with unique actions in vivo. CD-NP is a selecti
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... , March 4, 2015   Aratana Therapeutics, Inc ... company focused on the licensing, development and commercialization of ... it will present at the Barclays Global Healthcare ... the Loews Miami Beach Hotel in Miami ... Peter , M.D., President and Chief Executive Officer of ...
(Date:3/4/2015)... , March 4, 2015  Bayer HealthCare today ... (FDA) has accepted the company,s Biologics License Application ... compound.  Bayer is seeking FDA approval of the ... treatment of hemophilia A in children and adults. ... bringing new therapies to hemophilia A patients who ...
(Date:3/4/2015)... -- Halyard Health, Inc. (NYSE: HYH ) today ... and related key planning assumptions. "This is ... our fourth quarter results, our first as an independent ... a smooth separation from Kimberly-Clark and I,m pleased with ... growth and margin improvement in the fourth quarter while ...
Breaking Medicine Technology:Aratana Therapeutics to Present at the Barclays Global Healthcare Conference 2FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 2FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 3Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 2Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 3Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 4Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 5Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 6Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 7Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 8Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 9Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 10Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 11Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 12Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 13Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 14Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 15Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 16Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 17Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 18Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 19Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 20Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 21Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 22Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 23Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 24Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 25Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 26Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 27Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 28Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 29Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 30Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 31
(Date:3/4/2015)... The report covers spices market upstream ... industry development trend and proposals. The report provides ... definitions, applications and industry chain structure. Global market ... with a focus on history, developments, trends and ... the international and Chinese situation is also offered. ...
(Date:3/4/2015)... CITY, GA (PRWEB) March 04, 2015 ... exclusive advanced microfiber technology and their first compression therapy ... huge success of this collection, SIGVARIS USA is proud ... the MIDTOWN MICROFIBER product line. , Constructed from a ... with all-day comfort in mind. These socks and thigh-highs ...
(Date:3/4/2015)... New Port Richey, FL (PRWEB) March 04, 2015 ... Novus Medical Detox cut the ribbon on their new facility ... West Pasco Chamber of Commerce. The new facility will allow ... mission of helping end the prescription drug abuse epidemic through ... the current reality of drug addiction in the United States, ...
(Date:3/4/2015)... Today Visiopharm announces that Patrik Dahlén, previously the ... Visiopharm Board of Directors as Chairman. Mr. ... positioned to become the fastest growing software company, specializing ... , "Over the last several years, Visiopharm ... ONCOtopix™ Dx, a complete quantitative digital pathology solution for ...
(Date:3/4/2015)... A new dieting routine, called the feast and ... life. Studies conducted by the University of ... help extend life by increasing anti-oxidant production. While increased ... many suffering from obesity are already experiencing life shortening ... an alternative to the new Feast and Famine diet, ...
Breaking Medicine News(10 mins):Health News:World Spices Market Overview & Development 2015-2020 Now Available at DeepResearchReports.com 2Health News:World Spices Market Overview & Development 2015-2020 Now Available at DeepResearchReports.com 3Health News:Building on the Success of MIDTOWN MICROFIBER, SIGVARIS Expands Popular Compression Collection with Longer Foot Length Offerings 2Health News:Novus Medical Detox Hosts Ribbon Cutting Ceremony at Pasco County Facility 2Health News:Novus Medical Detox Hosts Ribbon Cutting Ceremony at Pasco County Facility 3Health News:Visiopharm Appoints Patrik Dahlen as Chairman of the Board 2Health News:Visiopharm Appoints Patrik Dahlen as Chairman of the Board 3Health News:Diet Doc Introduces New Alternative to the Feast and Famine Diet 2Health News:Diet Doc Introduces New Alternative to the Feast and Famine Diet 3
... A white paper that examines various state initiatives to expand ... President and Congress in support of state efforts, was distributed ... , The paper, State Experimentation with Reforms to Expand Access ... a part of any state-based reform. It is a summary ...
... only wear an eye patch for three to four hours ... in a study published on bmj.com today. , ... which is often recommended, is almost certainly excessive, they argue. ... between the eyes and the brain, which is often associated ...
... KENSINGTON, Md., Sept. 14 San Francisco will,get an ... tonight as,Psoriasis Cure Now, a nonprofit patient advocacy group, ... to celebrate. Starting at 9:30 pm, two bands,will perform ... this combination,awareness event, fundraiser and party. The suggested donation ...
... Sept. 14 Arrow International,Inc. (Nasdaq: ARRO ) ... voting advisory firm, has advised its clients to vote ... and for the re-election of Arrow,s current Board of ... 20, 2007. Proxy Governance is the fourth proxy ...
... Across the United States, He,s Riding AROUND IT, ... WASHINGTON, Sept. 14 Australian Geoff Thomas,will stop in ... by cycling to all four corners of the country ... kind to raise awareness for lupus, a chronic autoimmune,disease ...
... Sept. 14 As the political turmoil,surrounding stem cells ... - and treatment - that saved his life. John ... AuthorHouse -, http://www.authorhouse.com ), recounts the courageous five-year battle ... of cancer. Settling into a comfortable retirement with ...
Cached Medicine News:Health News:Internal medicine physicians recommend key elements to guide state initiatives 2Health News:Internal medicine physicians recommend key elements to guide state initiatives 3Health News:No need for children with lazy eye to wear patches all day 2Health News:San Francisco Psoriasis Event Tonight Will Celebrate First National Short Sleeve Day 2Health News:Proxy Governance Joins ISS, Glass Lewis and Egan Jones in Recommending Arrow International Shareholders Vote to Approve the $45.50 Per Share Merger With Teleflex 2Health News:Proxy Governance Joins ISS, Glass Lewis and Egan Jones in Recommending Arrow International Shareholders Vote to Approve the $45.50 Per Share Merger With Teleflex 3Health News:Bicyclist to Stop in DC during 9,000 Mile Lap Around the U.S. 2Health News:The Fight for His Life: Author, Family Battle Disease and Challenge Politics in the Face of Survival 2
... Stryker's cystoscope line combines ... intuitive and durable hardware. ... incorporate a robust, ergonomic ... connection found on Stryker ...
... The new EndoEYE Flexible Video Cystoscope from ... surgical technology. By marrying proprietary video chip ... Olympus is now providing a flexible video ... that of a rigid rod lens system. ...
The Olympus continuous flow cystoscope was especially designed for laser treatment of the prostate and for collagen injection....
... is an advanced transurethral microwave thermotherapy ... benign prostate hyperplasia (BPH). TherMatrx is ... thermotherapy treatment in the United States. ... does not require cutting, heavy sedation ...
Medicine Products: